Daniel F Hayes, MD
Rogel Cancer Center
1500 E. Medical Center Drive, #63122 CCC, SPC 5942
Ann Arbor, MI 48109-5942
Manage Your Profile
About
Dr. Daniel F. Hayes is the Stuart B. Padnos Professor of Breast Cancer Research.at the University of Michigan Rogel Cancer Center.
Dr. Hayes received undergraduate, master’s and medical degrees from Indiana University, followed by a residency in internal medicine at the University of Texas Southwestern Medical School/Health Science Center/Parkland Memorial Hospital and a fellowship in medical oncology at Harvard’s Dana Farber Cancer Institute (DFCI). He has led the breast cancer programs at DFCI (1991-1996), Georgetown University’s Lombardi Cancer Center (1996-2001), and the University of Michigan from 2001-2016.
Dr. Hayes’ research interests are in the field of experimental therapeutics and cancer biomarkers, especially in breast cancer. His work has been particularly focused on development and validation of cancer biomarker tests, such as HER-2, CA15-3, circulating tumor cells and pharmacogenomic markers. He has been instrumental in establishing international guidelines for the use of tumor biomarker tests, including criteria for their clinical utility.
He has served as chair of the SWOG Breast Cancer Translational Medicine Committee, and he was an inaugural member and chaired the American Society of Clinical Oncology (ASCO) Tumor Marker Guidelines Committee. He has been instrumental in the joint ad hoc committees between ASCO and the College of American Pathologists. Dr. Hayes served on the ASCO Board of Directors, and served a 3 year term as President of ASCO from 2016-2018. He is a Fellow of ASCO, a Fellow of the American College of Physicians, a past Komen Scholar, and a member of the Association of American Physicians and of the American Clinical and Climatologic Association. He has been the recipient of the ASCO Gianni Bonadonna Award in breast cancer and the Allen Lichter Visionary Leadership Award in 2021 as well as the Susan G. Komen Brinker Award for Scientific Distinction in Clinical Research in 2023, and has received the Distinguished Alumni Award from the Indiana University Medical School (2024).
Qualifications
-
Clinical Fellow in MedicineHarvard Medical School, Boston, United States
1982 - 1985
-
Fellow in Medical OncologyDana-Farber Cancer Institute, Boston, United States
1982 - 1985
-
Clinical Fellow in MedicineBrigham and Women's Hospital, Boston, United States
1982 - 1985
-
Senior Assistant ResidentParkland Memorial Hospital, Dallas, United States
1981 - 1982
-
Junior Assistant ResidentParkland Memorial Hospital, Dallas, United States
1980 - 1981
-
Intern in MedicineParkland Memorial Hospital, Dallas, United States
1979 - 1980
Center Memberships
-
Center MemberRogel Cancer Center
Research Overview
• Breast Cancer
• Tumor Biomarkers
• Liquid Biopsy/Circulating Tumor Biomarkers
• New Drug Development
Recent Publications
-
Sparano JA, Lama N, Gray RJ, Rahman MA, Wang V, Makower DF, Cheng Y, Shao S, Albain KS, Amidi E, Chen M, Hayes DF, Helmstetter A, Geyer CE, Bales C, Hinton A, Dees EC, Goetz MP, Olson JA, Badve SS, Saphner TJ, Whelan TJ, Kaklaman VG, Oberley M, Radovich M, Spetzler D, Mamounas EP, Wolmark N, Sledge GW. npj Breast Cancer, 2026 Aug 6;Journal ArticleAn Artificial Intelligence (AI) model integrating multiscale foundation model histopathology representations with molecular and clinical features predicts early and late distant recurrence in TAILORx
DOI:10.1038/s41523-026-01022-y -
Abdou Y, Hoag J, Barlow WE, Albain KS, Gralow JR, Meric-Bernstam F, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Schott AF, Racz J, Baehner FL, Tripathy D, Hortobagyi GN, Pusztai L, Sharma P, Kalinsky K. J Natl Cancer Inst, 2026 Jul 15;Journal ArticleRecurrence Score® gene group components and outcomes in the RxPONDER trial (SWOG S1007).
DOI:10.1093/jnci/djag221 PMID: 42458791 -
Kalinsky K, Barlow WE, Pathak HB, Puri RV, Mitra A, Home T, Gralow J, Albain KS, Hayes DF, Delaloge S, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Rastogi P, Schott AF, Brain E, Pierga J-Y, Ferrero J-M, Shak S, Tripathy D, Hortobagyi GN, Meric-Bernstam F, Sharma P, Pusztai L, Thompson A, Godwin AK. Annals of Oncology, 2026 Jul 26;Journal ArticleOvarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER) ☆
DOI:10.1016/j.annonc.2026.05.697 -
Bradley R, Braybrooke J, Clarke M, Hills RK, Kerr A, Peto R, Dodwell D, McGale P, Pan H, Taylor C, Arriagada R, Bliss J, Hackshaw A, Kim HA, Noh WC, Yarnold J, Beake G, Berry R, Boddington C, Davies C, Davies L, Duane F, Evans V, Gay J, Gettins L, Godwin J, Holt F, James S, Lui H, Lui Z, MacKinnon E, Mannu G, McHugh T, Morris P, Nakahara M, Read S, Straiton E, Taylor H, Masood MB, Parker D, Price JJ, Lohrisch C, Nichol A, Shan Y, Shao YF, Wang X, Xu B, Zhao DB, Howell A, Swindell R, Comis RL, Gray RJ, Robert NJ, Sledge GW, Solin LJ, Sparano JA, Tormey DC, Wood W, Delozier T, Spielman M, Mace Lesec'h J, Eiermann W, Hilfrich J, Jonat W, Kaufmann M, Kreienberg R, Schumacher M, A'Hern R, Ellis P, Kilburn L, Castiglione MM, Coates A, Colleoni M, Collins J, Forbes JJ, Gelber R, Goldhirsch A, Lindtner J, Pagani O, Price KN, Rudenstam CM, Senn HJ, Thürliman B, Chilvers CED, Coombes CR, Espie M, Hall E, Marty M, Mitsuyama S, Nomura Y, Ohno SI, Anderson S, Bandos H, Brown A, Bryant J, Cecchini R, Costantino J, Dignam J, Fisher B, Geyer C. Lancet, 2026 May 2; 407 (10540): 1699 - 1711.Journal ArticleEffects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 15 000 women in 23 randomised trials
DOI:10.1016/S0140-6736(26)00313-2 PMID: 42070572 -
Cani AK, Dolce EM, Darga EP, Hu K, Liu C, Robinson D, Wu Y, Paoletti C, Luker GD, Tomlins SA, Udager AM, Henderson NC, Thomas DG, Rae JM, Arul CM, Cobain EF, Hayes DF. Clinical Cancer Research, 2026 Feb 23; 32 (4_Supplement): ps2-07-22-ps2-07-22Journal ArticleAbstract PS2-07-22: Serial, multi-omic, multi-analyte, liquid biopsy monitoring of metastatic lobular breast cancer to detect clinically-relevant heterogeneity and evolution
DOI:10.1158/1557-3265.sabcs25-ps2-07-22 -
Kang IM, Forschmiedt JK, Loch MM, Lew DL, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Rastogi P, Schott AF, Baehner R, Sharma P, Tripathy D, Pusztai L, Hortobagyi GN, Kalinsky K, Henry NL. JAMA Oncol, 2025 Dec 11;Journal ArticleCognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial.
DOI:10.1001/jamaoncol.2025.5220 PMID: PMC12699395 -
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Electronic address: [email protected] , Early Breast Cancer Trialists' Collaborative Group (EBCTCG) . Lancet, 2025 Aug 9; 406 (10503): 603 - 614.Journal ArticleExtending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy.
DOI:10.1016/S0140-6736(25)01013-X PMID: 40783288 -
Hadley A, Buning G, Henderson NC, Milliron KJ, Hulswit BB, Hipp LE, Pleasant VA, Rae JM, Pilewskie ML, Hayes DF, Henry NL, Merajver SD, Cobain EF. Clinical Cancer Research, 2025 Oct 7; 31 (12_Supplement): p1-05-15-p1-05-15 - p1-05-15-p1-05-15.Journal ArticleA real-world analysis of cancer prevention measures among individuals with hereditary breast and ovarian cancer (HBOC) syndromes and no personal history of malignancy
DOI:10.1158/1557-3265.sabcs24-p1-05-15
Featured News & Stories
